Abstract:SummaryThis metadata record provides details of the data supporting the claims of the related manuscript: “Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment ”. The related study sought to increase the statistical power of detecting genes related to patient survival by combining information from different studies involving various immunotherapies. Type of data: RNA sequencing, clinical data Subject of data: Mus musculus: Mouse B6. Malt1-/-, sourced from Ruefli-Brasse et al., 2003; Mouse B6. Malt1fl/fl, sourced from Cheng et al., 2019; Mouse B6. Dectin3-/-, sourced from Zhu et al. 2013. Sample size: RNA-seq data of 19 mice tumour tissues (WT mice received IgG: n=6; WT mice received anti-PD-1: n=6; KO mice received IgG: n=3; KO mice received anti-PD-1: n=4) Data access The RNA sequencing data are openly available in the Gene Expression Omnibus (GEO) repository via the following accession: https://identifiers.org/geo:GSE158056. The clinical data and genotype data of TCGA tumour samples are contained in the files ‘Table S4_ImmunotherapyPrognosticMarker Genes_list.xlsx’, ‘TCGA_clinical_rawdata.rar’, ‘dNdS_value_AllCancerType.tar.gz’, ‘Table S1_raw_clincaldata_TCGA.xlsx’, ‘immunotherapy-SNP-103.txt’, shared together with this metadata record. The tumour growth in WT and KO mice are contained in the files ‘Clec4d_WT-KO_TumorSize.pzf’, ‘Malt1_WT-KO-TumorSize.pzfx’, ‘MeanFluorescenceIntensity.pzfx’, shared together with this metadata record. The gene expression tables of TCGA tumour samples are contained in the files ‘EBPlusPlusAdjustPANCAN_IlluminaHiSeq_RNASeqV2-v2.geneExp.tsv.gz’, ‘TCGA_pancancer.FractionCorrection_logqq.exp.txt.gz’, ‘TCGA_pancancer.MutationCorrection_logqq.exp.txt.gz’, shared together with this metadata record. In addition to being available via the related publication, Supplementary Tables 1-6 are also available via this data record.Corresponding author(s) for this study Xun Lan, Tel: 86-10-62770517; Fax: 86-10-62791875; E-mail: xlan@tsinghua.edu.cn. Xin Lin, Tel: 86-10-62796319; Fax: 86-10-62794262; E-mail: linxin307@tsinghua.edu.cn.

Supplementary Data from RAB37 Hypermethylation Regulates Metastasis and Resistance to Docetaxel-Based Induction Chemotherapy in Nasopharyngeal Carcinoma

Supplementary Data from an Alternatively Spliced P62 Isoform Confers Resistance to Chemotherapy in Breast Cancer

Supplementary Data - Materials and Methods from Epigenetically Regulated Chromosome 14q32 miRNA Cluster Induces Metastasis and Predicts Poor Prognosis in Lung Adenocarcinoma Patients

Supplementary Data from Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC

Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Supplementary Data from Regorafenib Promotes Antitumor Immunity Via Inhibiting PD-L1 and IDO1 Expression in Melanoma

A Comprehensive RNA Study to Identify circRNA and miRNA Biomarkers for Docetaxel Resistance in Breast Cancer

Supplementary Table S2 from CD24hiCD27+ Bregs Within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer

Supplementary Figure S12 from CD24hiCD27+ Bregs Within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer

Supplementary Data from Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (neoatp): Primary Analysis of a Phase II Study

Supplemental Data 1 from the RARS–MAD1L1 Fusion Gene Induces Cancer Stem Cell–like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma

Supplementary Table S4 from CD24hiCD27+ Bregs Within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer

Targeting treatment resistance: unveiling the potential of RNA methylation regulators and TG-101,209 in pan-cancer neoadjuvant therapy

Supplementary Data DS1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Supplementary Data from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study

Genomic methylation profiling combined with gene expression microarray reveals the aberrant methylation mechanism involved in nasopharyngeal carcinoma taxol resistance.

Supplementary Data 3 from CD36+ Proinflammatory Macrophages Interact with ZCCHC12+ Tumor Cells in Papillary Thyroid Cancer Promoting Tumor Progression and Recurrence

Video-assisted thoracoscopic surgery for complex mediastinal mass resections.

Supplementary Data from Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer

Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Metadata Record for the Manuscript: Knockout of Immunotherapy Prognostic Marker Genes Eliminates the Effect of the Anti-Pd-1 Treatment